Platinum
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Platinum
- DrugBank Accession Number
- DB12257
- Background
Platinum is under investigation for the treatment of Metastatic Breast Cancer, Non-small Cell Lung Cancer, Gastric Large Cell Neuroendocrine Carcinoma, Colorectal Large Cell Neuroendocrine Carcinoma, and Pancreatic Large Cell Neuroendocrine Carcinoma, among others. Platinum has been investigated for the treatment and supportive care of Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Primary Cancer, Non Small Cell Lung Cancer, and Primary Peritoneal Carcinoma, among others.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 195.084
Monoisotopic: 194.964774449 - Chemical Formula
- Pt
- Synonyms
- platino
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmbroxol The risk or severity of methemoglobinemia can be increased when Platinum is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Platinum is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Platinum is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Platinum is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Platinum is combined with Bupivacaine. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as homogeneous transition metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a transition metal atom.
- Kingdom
- Inorganic compounds
- Super Class
- Homogeneous metal compounds
- Class
- Homogeneous transition metal compounds
- Sub Class
- Not Available
- Direct Parent
- Homogeneous transition metal compounds
- Alternative Parents
- Not Available
- Substituents
- Homogeneous transition metal
- Molecular Framework
- Not Available
- External Descriptors
- elemental platinum (CHEBI:33400)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 49DFR088MY
- CAS number
- 7440-06-4
- InChI Key
- BASFCYQUMIYNBI-UHFFFAOYSA-N
- InChI
- InChI=1S/Pt
- IUPAC Name
- platinum
- SMILES
- [Pt]
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0013671
- PubChem Compound
- 23939
- PubChem Substance
- 347828531
- ChemSpider
- 22381
- 1311280
- ChEBI
- 33364
- PharmGKB
- PA150595617
- Wikipedia
- Platinum
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Treatment Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) 1 4 Not Yet Recruiting Treatment Non-Small Cell Lung Cancer (NSCLC) 1 4 Recruiting Treatment Hemophagocytic Syndrome (HPS) / NK/T-cell Lymphoma 1 4 Recruiting Treatment Non-Small Cell Lung Cancer (NSCLC) 1 4 Unknown Status Treatment Non-Small Cell Lung Cancer (NSCLC) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP 0.03 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 0 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 0 m3·mol-1 Chemaxon Polarizability 1.78 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at October 20, 2016 21:44 / Updated at June 12, 2020 16:53